Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.30 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2027979 | 0.86 | ALDH1A1 (0.46) | ALDH1A1HPGDTDP1TSHRGPR35 | |
| SCHEMBL6652362 | 0.83 | ALDH1A1 (0.56) | ALDH1A1HPGDTDP1TSHRGPR35 | |
| SCHEMBL7291481 | 0.81 | ALDH1A1 (0.72) | ALDH1A1HPGDTDP1TSHRGPR35 | |
| SCHEMBL11812967 | 0.80 | ALDH1A1 (0.56) | ALDH1A1HPGDTDP1TSHRGPR35 | |
| SCHEMBL6104259 | 0.80 | ALDH1A1 (0.58) | ALDH1A1HPGDTDP1TSHRLMNA | |
| SCHEMBL9104270 | 0.80 | ALDH1A1 (0.40) | ALDH1A1HPGDTDP1TSHRGPR35 | |
| SCHEMBL30681717 | 0.80 | ALDH1A1 (0.56) | ALDH1A1HPGDTDP1TSHRGPR35 | |
| SCHEMBL10958461 | 0.80 | ALDH1A1 (0.56) | ALDH1A1HPGDTDP1TSHRGPR35 | |
| SCHEMBL30954343 | 0.80 | ALDH1A1 (0.40) | ALDH1A1HPGDTDP1TSHRGPR35 | |
| SCHEMBL11154245 | 0.80 | ALDH1A1 (0.56) | ALDH1A1HPGDTDP1TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040199002-A1 | Process for producing(2-nitrophenyl)acetonitrile derivative and intermediate therefor | INDUSTRY CO., LTD. (JP) | 2004-10-07 | — | — | US | disclosed |
| EP-1431278-A1 | PROCESS FOR PRODUCING (2-NITROPHENYL)ACETONITRILE DERIVATIVE AND INTERMEDIATE THEREFOR | IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) | 2004-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040199002-A1 | Process for producing(2-nitrophenyl)acetonitrile derivative and intermediate therefor | DOHH, NCEH1, NOTUM | ALDH1A1 371/4885HPGD 90/4885TDP1 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.